View source for Staidson (Beijing) Biopharmaceuticals Co., Ltd. (20240226236). NERVE GROWTH FACTOR FUSION PROTEIN, PREPARATION METHOD AND USE THEREOF simplified abstract

=NERVE GROWTH FACTOR FUSION PROTEIN, PREPARATION METHOD AND USE THEREOF=


==Organization Name==

[[:Category:Staidson (Beijing) Biopharmaceuticals Co., Ltd.|Staidson (Beijing) Biopharmaceuticals Co., Ltd.]]


[[Category:Staidson (Beijing) Biopharmaceuticals Co., Ltd.]]

==Inventor(s)==

[[:Category:Qingshuang Zhang of Beijing (CN)|Qingshuang Zhang of Beijing (CN)]][[Category:Qingshuang Zhang of Beijing (CN)]]

[[:Category:Lei Ma of Beijing (CN)|Lei Ma of Beijing (CN)]][[Category:Lei Ma of Beijing (CN)]]

[[:Category:Ming Liu of Beijing (CN)|Ming Liu of Beijing (CN)]][[Category:Ming Liu of Beijing (CN)]]

==NERVE GROWTH FACTOR FUSION PROTEIN, PREPARATION METHOD AND USE THEREOF - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240226236 titled 'NERVE GROWTH FACTOR FUSION PROTEIN, PREPARATION METHOD AND USE THEREOF

The present disclosure pertains to a nerve growth factor (NGF) fusion protein and its preparation method and use in the field of biopharmaceuticals. The fusion protein consists of NGF, a linker peptide, and an FC moiety of IgG or its analogues or fragments.

* Higher biological activity compared to wild-type NGF
* Half-life extended more than 17 times
* Reduced administration frequency
* Increased efficacy

Potential Applications:
- Treatment of neurodegenerative diseases
- Nerve regeneration therapies
- Pain management

Problems Solved:
- Short half-life of wild-type NGF
- Low efficacy of traditional NGF treatments

Benefits:
- Improved treatment outcomes
- Enhanced patient compliance
- Reduced healthcare costs

Commercial Applications:
Title: Enhanced Nerve Growth Factor Fusion Protein for Biopharmaceuticals
This technology can be utilized in pharmaceutical companies for the development of novel therapies for neurodegenerative diseases, nerve regeneration, and pain management, potentially leading to new revenue streams and market opportunities.

Prior Art:
Researchers can explore existing literature on NGF fusion proteins, linker peptides, and IgG FC moieties in the field of biopharmaceuticals to understand the background of this innovation.

Frequently Updated Research:
Stay updated on the latest advancements in NGF fusion protein research, clinical trials, and applications in biopharmaceuticals to leverage the full potential of this technology.

Questions about NGF Fusion Protein:
1. How does the NGF fusion protein differ from traditional NGF treatments?
The NGF fusion protein offers higher biological activity, an extended half-life, and increased efficacy compared to wild-type NGF, addressing key limitations of traditional treatments.

2. What are the potential commercial implications of this technology in the biopharmaceutical industry?
The NGF fusion protein has the potential to revolutionize the treatment landscape for neurodegenerative diseases, nerve regeneration, and pain management, creating new opportunities for pharmaceutical companies and healthcare providers.


==Original Abstract Submitted==

the present disclosure relates to the field of biopharmaceuticals and provides a nerve growth factor (ngf) fusion protein and a preparation method and use thereof. the fusion protein has a general formula represented by a-b or a-l-b, wherein a is a nerve growth factor, l is a linker peptide, and b is an fc moiety of igg, or an analogue of the fc moiety of igg, or a fragment of the fc moiety of igg. the fusion protein of the present disclosure has the following advantages over a wild-type ngf: higher biological activity, a half-life extended more than 17 times, greatly reduced administration frequency, and significantly increased efficacy.



[[Category:A61K38/18]]
[[Category:A61P25/00]]
[[Category:C07K14/48]]
[[Category:C12N15/85]]
[[Category:CPC_A61K38/18]]